3 hours Capricor Therapeutics Initiates FDA Rolling Submission for Duchenne Muscular Dystrophy Treatment MarketBeat
On October 9, 2024, Capricor Therapeutics, Inc. (NASDAQ: CAPR) made a significant announcement regarding its progress with the U.S. Food and Drug Administration (FDA). The company revealed that it has commenced the rolling submission process for a Biol…